BioClonetics Immunotherapeutics

Designing the first cure for HIV through the use of monoclonal antibodies

Last Funded September 2017

$386,766

raised from 588 investors

Highlights

1
We have created a cell line that produces an anti-HIV antibody called Clone 3.
2
We have demonstrated that Clone 3 neutralizes all clades and groups of HIV isolates.
3
We have identified that Clone 3 targets HIV at an immutable site on the HIV virus.
4
We expect to complete animal trials within 18 to 24 months.

Our Team


Downloads

Overview